|
Council on Emergency Medical Care
|
Committee, Work group, Advisory group, or Task Force
|
ACF, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA
|
OD/OSP, NCATS, NHLBI, NICHD, NIGMS, NIMH, NINDS, NLM
|
The Council on Emergency Medical Care (CEMC) is a coalition comprised of subject-matter experts and policy makers in emergency medical care from organizations across the Federal Government. The CEMC provides strategic and operational support to the HHS Emergency Care Coordinating Committee (ECCC) through policy-level guidance and interdepartmental and interagency collaboration for ongoing and future Federal efforts that address daily emergency medical care issues in the US. This entity contributes to the development, advancement, and coordination of Federal strategies, policies, and priorities relating to emergency medical care to improve the nation''s emergency care system.
|
|
Countermeasures Against Chemical Threats (CounterACT) Research Network Annual Symposium
|
Meeting/ Workshop
|
CDC, FDA, OS
|
OD/OSP, NEI, NIAID, NIAMS, NICHD, NIEHS, NIGMS, NINDS
|
This workshop was organized by NINDS as part of the Countermeasures Against Chemical Threats (CounterACT) Research Network, a group formed to conduct basic, translational, and clinical research aimed at the discovery and/or identification of better therapeutic and diagnostic medical countermeasures against chemical threat agents. The 3-day meeting allowed researchers to share information, encouraged collaboration, and enabled NIH staff to evaluate the group’s progress on themes such as nerve agents, seizure detection technology, cyanide, and sulfur mustard.
|
|
Countermeasures Against Chemical Threats (CounterACT) Research Network Working Group
|
Other
|
OS
|
NICHD, NEI, NIAID, NIAMS, NIEHS, NIGMS, NINDS
|
Function is to prioritize/fund/manage studies focusing on the development of medical countermeasures (MCMs) for protection against chemical agents.
|
|
Creutzfeldt-Jakob Disease Surveillance in Recipients of Human Growth Hormone, National Hormone and Pituitary Program (NHPP)
|
Resource Development
|
CDC, FDA
|
NIDDK
|
From 1963 to 1985, the National Hormone and Pituitary Program (NHPP), funded by the U.S. Department of Health and Human Services (HHS), sent human growth hormone (hGH) made from human pituitary glands to hundreds of doctors across the country. As a part of research studies, doctors used the hormone to treat nearly 7,700 children for failure to grow.
In 1985, the HHS learned that three people treated with pituitary hGH died of CJD, a rare, incurable brain disease. The HHS immediately stopped distributing the hormone and began a national study to learn more about how pituitary hGH treatment may have caused this problem.
|
|
Criminal Justice-Drug Abuse Treatment Studies (CJ-DATS)
|
Research Initiative
|
SAMHSA
|
NIDA
|
Research network seeking to determine the best way to integrate evidence-based drug abuse treatment into criminal justice settings including practices related to screening and assessment, HIV intervention, and medication assisted treatment for opioid dependence.
|
|
DAIDS (NIH/NIAID) and DTBE (CDC/NCHHSTP) Partnership for Tuberculosis (TB) and TB/HIV Research
|
Research Initiative
|
CDC
|
NIAID
|
This research initiative will conduct pyrazinamide (PZA) resistance profiling.
|
|
DailyMed
|
Resource Development
|
FDA
|
NLM
|
DailyMed provides high quality information about marketed drugs, including FDA labels (package inserts). The Web site provides health information providers and the public with a standard, comprehensive, up-to-date, look-up and download resource of medication content and labeling as found in medication package inserts. NLM provides this DailyMed a public service, free of advertising.
|
|
Data Access for Grantees
|
Resource Development
|
CMS
|
NIA
|
NIA developed a Memorandum of Understanding (MOU) to assist grantees with accessing CMS data. It is anticipated that this initiative will create a more user friendly and more cost efficient means for grantees to access CMS data especially the need to access Part D data. Specifically, this MOU gives CMS''s Privacy Board justification to release Part D data to NIA grantees with Data Use Agreements. Researchers pay for data use.
|
|
Data Mining on FDA''s 510K Documents for Laboratory Tests
|
Research Initiative
|
FDA
|
NLM
|
U.S. Food and Drug Administration (FDA) provides a large corpus of text about decision summaries on the applications for in vitro diagnostic (laboratory) products. This corpus of text contains valuable information about the nature of laboratory testing devices and test products such as analyte and specimen names that are tested, unit of measures, and analyte detection limits of the presented devices and products. In this project NLM is trying to recognize and extract this information algorithmically and provide them to the operators who are responsible to collect this information and enter it into the LOINC database manually.
|
|
Data Quality Reviews of ARRA s 1512 Recipient Reports
|
Resource Development
|
ACF, AHRQ, CDC, CMS, HRSA, OS
|
OD/OER
|
Participate in review of the quarterly reports submitted to www.federalreporting.gov in compliance with s.1512 of the American Recovery and Reinvestment Act (ARRA) of 2009.
|